🇺🇸 Abobotulinum toxin A in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 21 April 2025 – 21 April 2026
• Total reports: 12

Most-reported reactions

1. Condition Aggravated — 2 reports (16.67%)
2. Muscular Weakness — 2 reports (16.67%)
3. Activities Of Daily Living Impaired — 1 report (8.33%)
4. Arm Amputation — 1 report (8.33%)
5. Drug Ineffective — 1 report (8.33%)
6. Dysphagia — 1 report (8.33%)
7. Dystonia — 1 report (8.33%)
8. Eye Swelling — 1 report (8.33%)
9. Fatigue — 1 report (8.33%)
10. Mass — 1 report (8.33%)

Source database →

Frequently asked questions

Is Abobotulinum toxin A approved in United States?

Abobotulinum toxin A does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Abobotulinum toxin A in United States?

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is the originator. The local marketing authorisation holder may differ — check the official source linked above.